Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 30 | 2023 | 107 | 12.000 |
Why?
|
| Adenoma | 16 | 2023 | 56 | 8.700 |
Why?
|
| Colonoscopy | 30 | 2023 | 65 | 8.060 |
Why?
|
| Colonic Polyps | 13 | 2023 | 27 | 5.950 |
Why?
|
| Early Detection of Cancer | 15 | 2023 | 99 | 3.750 |
Why?
|
| Neoplasms, Second Primary | 5 | 2022 | 38 | 2.730 |
Why?
|
| Mass Screening | 7 | 2023 | 160 | 2.130 |
Why?
|
| DNA Methylation | 5 | 2022 | 151 | 1.810 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 14 | 1.570 |
Why?
|
| Barrett Esophagus | 3 | 2020 | 15 | 1.530 |
Why?
|
| Capsule Endoscopy | 2 | 2021 | 4 | 1.410 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.290 |
Why?
|
| Humans | 46 | 2023 | 25165 | 1.260 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 39 | 1.100 |
Why?
|
| Colon | 4 | 2018 | 108 | 1.080 |
Why?
|
| Population Surveillance | 3 | 2018 | 113 | 1.070 |
Why?
|
| Adenomatous Polyps | 3 | 2017 | 4 | 1.070 |
Why?
|
| Esophagoscopy | 3 | 2020 | 12 | 1.030 |
Why?
|
| Middle Aged | 23 | 2021 | 8303 | 0.990 |
Why?
|
| Guideline Adherence | 2 | 2016 | 51 | 0.980 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 26 | 0.860 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2022 | 2 | 0.800 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2022 | 2 | 0.780 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 46 | 0.760 |
Why?
|
| Aged | 19 | 2021 | 8448 | 0.740 |
Why?
|
| Male | 22 | 2021 | 13815 | 0.730 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 7 | 0.730 |
Why?
|
| Female | 22 | 2021 | 14161 | 0.720 |
Why?
|
| Intestine, Small | 1 | 2021 | 29 | 0.710 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 3 | 0.680 |
Why?
|
| Carcinoma | 2 | 2022 | 66 | 0.680 |
Why?
|
| Quality of Health Care | 2 | 2022 | 90 | 0.670 |
Why?
|
| Gastroenterology | 2 | 2019 | 3 | 0.650 |
Why?
|
| No-Show Patients | 1 | 2019 | 1 | 0.640 |
Why?
|
| Censuses | 1 | 2019 | 9 | 0.640 |
Why?
|
| Poverty Areas | 1 | 2019 | 9 | 0.630 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 88 | 0.560 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3185 | 0.560 |
Why?
|
| Residence Characteristics | 1 | 2019 | 200 | 0.560 |
Why?
|
| Clinical Competence | 2 | 2016 | 182 | 0.560 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 25 | 0.560 |
Why?
|
| Cecum | 1 | 2016 | 10 | 0.540 |
Why?
|
| Lymphoid Tissue | 1 | 2016 | 9 | 0.530 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 21 | 0.520 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 37 | 0.510 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 134 | 0.510 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 1 | 0.490 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 58 | 0.480 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 25 | 0.480 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 184 | 0.480 |
Why?
|
| Hyperplasia | 3 | 2021 | 17 | 0.470 |
Why?
|
| Biopsy | 4 | 2021 | 181 | 0.460 |
Why?
|
| Risk Factors | 5 | 2021 | 2179 | 0.460 |
Why?
|
| Patient Compliance | 1 | 2015 | 143 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 105 | 0.440 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 11 | 0.440 |
Why?
|
| Intestines | 1 | 2014 | 76 | 0.440 |
Why?
|
| Esophagus | 1 | 2012 | 55 | 0.390 |
Why?
|
| Prospective Studies | 5 | 2023 | 1618 | 0.380 |
Why?
|
| Intestinal Mucosa | 4 | 2022 | 152 | 0.360 |
Why?
|
| Cohort Studies | 5 | 2018 | 1772 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 243 | 0.350 |
Why?
|
| Colectomy | 1 | 2010 | 19 | 0.350 |
Why?
|
| Colitis, Ulcerative | 1 | 2010 | 59 | 0.340 |
Why?
|
| United States | 4 | 2020 | 1928 | 0.320 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 126 | 0.310 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 331 | 0.310 |
Why?
|
| Logistic Models | 3 | 2015 | 377 | 0.290 |
Why?
|
| Incidence | 3 | 2019 | 704 | 0.290 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 29 | 0.280 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 39 | 0.270 |
Why?
|
| Area Under Curve | 2 | 2019 | 58 | 0.270 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2023 | 2 | 0.270 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 121 | 0.230 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 836 | 0.230 |
Why?
|
| Intestinal Polyposis | 1 | 2023 | 1 | 0.220 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 4 | 0.220 |
Why?
|
| Surgical Instruments | 1 | 2023 | 24 | 0.210 |
Why?
|
| Adult | 6 | 2020 | 7259 | 0.210 |
Why?
|
| Prognosis | 4 | 2018 | 693 | 0.200 |
Why?
|
| Treatment Outcome | 2 | 2023 | 3204 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 30 | 0.200 |
Why?
|
| MicroRNAs | 1 | 2022 | 41 | 0.190 |
Why?
|
| Gastrointestinal Transit | 1 | 2021 | 11 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 19 | 0.180 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 1 | 0.180 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 3 | 0.180 |
Why?
|
| Observer Variation | 1 | 2021 | 89 | 0.180 |
Why?
|
| Ikaros Transcription Factor | 1 | 2020 | 1 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2020 | 578 | 0.180 |
Why?
|
| Transaminases | 1 | 2020 | 6 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 6 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4508 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2021 | 208 | 0.170 |
Why?
|
| Magnets | 1 | 2020 | 3 | 0.170 |
Why?
|
| Epithelial Cells | 2 | 2013 | 71 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 5 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 318 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 12 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2020 | 128 | 0.160 |
Why?
|
| ROC Curve | 1 | 2019 | 133 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 89 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 641 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 11 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2018 | 57 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 77 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 82 | 0.140 |
Why?
|
| Sex Factors | 2 | 2018 | 430 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 56 | 0.140 |
Why?
|
| CpG Islands | 1 | 2017 | 49 | 0.140 |
Why?
|
| Age Factors | 2 | 2018 | 712 | 0.130 |
Why?
|
| Gastroenterologists | 1 | 2016 | 2 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 78 | 0.130 |
Why?
|
| Documentation | 1 | 2016 | 23 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 64 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 2015 | 10 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 14 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 557 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 450 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2015 | 241 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 852 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 11 | 0.120 |
Why?
|
| Metaplasia | 1 | 2014 | 7 | 0.110 |
Why?
|
| Stomach | 1 | 2014 | 13 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 450 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 72 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 171 | 0.110 |
Why?
|
| Mast Cells | 1 | 2013 | 17 | 0.100 |
Why?
|
| Colitis | 1 | 2013 | 27 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 38 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 49 | 0.100 |
Why?
|
| Macrophages | 1 | 2013 | 87 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1336 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 637 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 120 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1672 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 24 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 46 | 0.070 |
Why?
|
| Diarrhea | 1 | 2007 | 33 | 0.070 |
Why?
|
| Acute Disease | 1 | 2007 | 165 | 0.070 |
Why?
|
| Apoptosis | 1 | 2007 | 193 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 237 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 114 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 114 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1301 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 72 | 0.070 |
Why?
|
| Reoperation | 1 | 2010 | 847 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 85 | 0.060 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 3 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 203 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 3 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 88 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 20 | 0.050 |
Why?
|
| Endosonography | 1 | 2020 | 8 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 6 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 59 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 1 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 13 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 46 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 172 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 113 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 21 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 88 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 104 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 342 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 324 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 106 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 11 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 21 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 84 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 91 | 0.030 |
Why?
|
| Piroxicam | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tryptases | 1 | 2013 | 5 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chromones | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 11 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 26 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 320 | 0.030 |
Why?
|
| Cell Movement | 1 | 2013 | 76 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 164 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 234 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 278 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 50 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 387 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 87 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 401 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1300 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 3430 | 0.020 |
Why?
|
| Causality | 1 | 2005 | 53 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 25 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 99 | 0.010 |
Why?
|
| Health Surveys | 1 | 2005 | 82 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 123 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 458 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 916 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 245 | 0.010 |
Why?
|